MedTrace Logo

Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease

NCT01110252 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2012-03-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the cell therapy with bone marrow mononuclear cells is safe in the treatment of chronic obstructive pulmonary disease, specifically the pulmonary emphysema.

Conditions

Interventions

DRUG

Stem cells stimulation

Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.

PROCEDURE

stem cells collection

pullout of 200ml of bone marrow through the puncture of the iliac crest

GENETIC

stem cells infusion

slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.

Sponsors & Collaborators

  • Laboratório de Genética Humana e Terapia Celular, Unesp - Assis

    collaborator UNKNOWN

  • Instituto de Molestias Cardiovasculares

    collaborator OTHER

  • UPECLIN HC FM Botucatu Unesp

    lead OTHER

Principal Investigators

  • João T Ribeiro-Paes, PhD MD · geneticist

  • Aldemir Bilaqui, MD · surgeon

  • Oswaldo T Greco, MD · cardiologist

  • Milton A Ruiz, MD · hematologist

  • José D Araújo, MD · surgeon

  • Mario R Lago, Ms · technician

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-10-31
Completion
2011-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01110252 on ClinicalTrials.gov